SEC Form 4 · accession 0001193125-26-318103
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert W Postma
Director
Period of report
Jul 23, 2026
Accepted (ET)
Jul 27, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 23, 2026 | A | 8,463 | $1.92 | A | 58,609 | D | |
| Common Stock | holding | — | — | — | 24 | I | By spouse's IRA | |
| Common StockF2 | holding | — | — | — | 62,416 | I | By WaterMill Asset Management Corp.(2) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock issued in lieu of board fees.
- F2The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill